Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
|
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [1] Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine
    Kandasamy, Mani
    Srinivas, P.
    Subramaniam, Kala
    Ravi, Sandhya
    John, James
    Shekar, Radha
    Srinivas, Nuggehally
    Thangam, Saral
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (09) : 879 - 887
  • [2] Association between CYP2D6 genotype and venlafaxine and O-desmethylvenlafaxine concentrations and efficacy: Results from two French studies
    Konecki, C.
    Colle, R.
    Chappell, K.
    Tayeb, A. E. K. Ait
    Becquemont, L.
    Corruble, E.
    Verstuyft, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 41 - 42
  • [3] The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort
    Kringen, Marianne K.
    Braten, Line S.
    Haslemo, Tore
    Molden, Espen
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 137 - 144
  • [4] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    Hermann, M.
    Hendset, M.
    Fosaas, K.
    Hjerpset, M.
    Refsum, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (05) : 483 - 487
  • [5] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    M. Hermann
    M. Hendset
    K. Fosaas
    M. Hjerpset
    H. Refsum
    European Journal of Clinical Pharmacology, 2008, 64 : 483 - 487
  • [6] Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans
    Eap, CB
    Lessard, E
    Baumann, P
    Brawand-Amey, M
    Yessine, MA
    O'Hara, G
    Turgeon, J
    PHARMACOGENETICS, 2003, 13 (01): : 39 - 47
  • [7] Venlafaxine serum levels and CYP2D6 genotype
    Veefkind, AH
    Hafmans, PMJ
    Hoencamp, E
    THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 202 - 208
  • [8] Venlafaxine oxidation in vitro is catalysed by CYP2D6
    Otton, SV
    Ball, SE
    Cheung, SW
    Inaba, T
    Rudolph, RL
    Sellers, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (02) : 149 - 156
  • [9] Effect of CYP2D6 variants on venlafaxine metabolism in vitro
    Zhan, Yun-Yun
    Liang, Bing-Qing
    Wang, Hao
    Wang, Zhen-He
    Weng, Qing-Hua
    Dai, Da-Peng
    Cai, Jian-Ping
    Hu, Guo-Xin
    XENOBIOTICA, 2016, 46 (05) : 424 - 429
  • [10] Venlafaxine and CYP2D6 in clinical practice: a case report
    Zeppegno, P.
    Rolla, R.
    Dalo, V.
    Ressico, F.
    Parafioriti, A.
    Prosperini, P.
    Vidali, M.
    Bellomo, G.
    Torre, E.
    JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA, 2011, 17 (04): : 450 - 452
12345